Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alex Yang
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Beta
- -9.19
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 57.50
Financials
PLYX has only 8 quarterly periods on file — the charts below show the full history available.
Net Income
$-1.38MEBITDA
$-1.38MFree Cash Flow
$-1.37MEPS (diluted)
$-0.03Shares Outstanding (diluted)
48.28M-74.5%Operating Expenses
$1.38MCash & Debt
$11.54MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-8.98M | $-0.19 |
| 2024 | $0.00 | $-30.36M | $-0.16 |
| 2023 | $0.00 | $-3.78M | $-0.02 |
Valuation
PLYXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-40.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·6h ago·Negative
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles
View source ↗ - Newsglobenewswire.com·7d ago·Neutral
…tion, CRO engagement and Fast Track Designation across all four planned indication PARAMUS, NJ, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders (“LSDs”), today provided an operational readiness update for SOTERIA, its Phase 2 basket trial evaluating lead candidate PLX-200 across four rare pediatric LSDs. Polaryx continues to advance clin…
View source ↗
Earnings
Typical surprise -150.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.03 vs $-0.04beat
- Fri, May 15$-0.05 vs $-0.02miss
- Tue, Mar 24$-0.13 vs $-0.02miss
Estimates and results for PLYX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.